Delving into the Latest Updates on YKYY029 with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms-

Target

AGT

Action

inhibitors

Mechanism

AGT inhibitors(Angiotensinogen inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

HypertensionEssential Hypertension

Inactive Indication-

Originator Organization

Yuekang Pharmaceutical Group Co., Ltd.

Active Organization

Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

Hangzhou Tianlong Pharmaceutical Co., Ltd.

Yuekang Pharmaceutical Group Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

主要目的评价YKYY029注射液在轻中度高血压患者中，治疗第3个月时对收缩压（SBP）的影响；次要目的评价YKYY029注射液在轻中度高血压患者中，治疗第3个月时对舒张压（DBP）的影响。评价YKYY029注射液在轻中度高血压患者中，治疗后第6个月、9个月、12个月对SBP和DBP的影响。评价YKYY029注射液在轻中度高血压患者中，治疗后第3个月、6个月、9个月、12个月SBP、DBP的动态变化。评价YKYY029注射液对血压昼夜节律的影响。评价YKYY029注射液在轻中度高血压患者中多次给药治疗的安全性。评价YKYY029注射液在参与者中的药代动力学（PK）特征。评价YKYY029注射液在参与者中的药效动力学（PD）特征。评价YKYY029注射液在参与者中的免疫原性。

[Translation]

Primary Objective: To evaluate the effect of YKYY029 injection on systolic blood pressure (SBP) at month 3 in patients with mild to moderate hypertension. Secondary Objectives: To evaluate the effect of YKYY029 injection on diastolic blood pressure (DBP) at month 3 in patients with mild to moderate hypertension. To evaluate the effect of YKYY029 injection on SBP and DBP at months 6, 9, and 12 in patients with mild to moderate hypertension. To evaluate the dynamic changes in SBP and DBP at months 3, 6, 9, and 12 in patients with mild to moderate hypertension. To evaluate the effect of YKYY029 injection on the diurnal rhythm of blood pressure. To evaluate the safety of repeated-dose treatment with YKYY029 injection in patients with mild to moderate hypertension. To evaluate the pharmacokinetic (PK) characteristics of YKYY029 injection in participants. To evaluate the pharmacodynamic (PD) characteristics of YKYY029 injection in participants. To evaluate the immunogenicity of YKYY029 injection in participants.

Start Date21 Apr 2026

Sponsor / Collaborator

Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

[+1]

ChiCTR2600122200

/ Not yet recruitingPhase 2IIT

A multicenter, randomized, double‑blind, placebo‑controlled, Phase II clinical study to evaluate the efficacy and safety of YKYY029 Injection in patients with mild to moderate hypertension

Start Date01 Mar 2026

Sponsor / Collaborator

Peking University Third Hospital

[+2]

CTR20252860

/ Active, not recruitingPhase 1

评估YKYY029注射液单次皮下注射在中国健康志愿者及原发性轻度高血压患者中的安全性、耐受性、药代动力学/药效学的I期临床研究

[Translation] A Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of a single subcutaneous injection of YKYY029 injection in Chinese healthy volunteers and patients with essential mild hypertension

评价YKYY029注射液的安全性、耐受性、药代动力学/药效学

[Translation]

To evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics of YKYY029 injection

Start Date24 Jul 2025

Sponsor / Collaborator

Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with YKYY029

Login to view more data

100 Translational Medicine associated with YKYY029

Login to view more data

100 Patents (Medical) associated with YKYY029